Evidence map›Paper›PMID 36291876›Full record

ArticleCancers2022

miR-214-Enriched Extracellular Vesicles Released by Acid-Adapted Melanoma Cells Promote Inflammatory Macrophage-Dependent Tumor Trans-Endothelial Migration.

Elena Andreucci, Jessica Ruzzolini, Francesca Bianchini, Giampaolo Versienti, Alessio Biagioni, Matteo Lulli, Daniele Guasti, Patrizia Nardini, Simona Serratì, Francesca Margheri and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. The chimeric aptamer axl-miR-214sponge inhibits breast cancer and melanoma dissemination.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  8. Omics in Cutaneous Melanoma.Asian Pacific journal of cancer prevention : APJCP · 2025
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Elena AndreucciDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", Università degli Studi di Firenze, 50134 Florence, Italy.ORCID 0000-0003-3980-3073
Jessica RuzzoliniDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", Università degli Studi di Firenze, 50134 Florence, Italy.
Francesca BianchiniDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", Università degli Studi di Firenze, 50134 Florence, Italy.ORCID 0000-0002-5839-4298
Giampaolo VersientiDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", Università degli Studi di Firenze, 50134 Florence, Italy.
Alessio BiagioniDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", Università degli Studi di Firenze, 50134 Florence, Italy.ORCID 0000-0002-6193-7417
Matteo LulliDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", Università degli Studi di Firenze, 50134 Florence, Italy.ORCID 0000-0002-8528-4094
Daniele GuastiDepartment of Experimental and Clinical Medicine, Università degli Studi di Firenze, 50134 Florence, Italy.
Patrizia NardiniDepartment of Experimental and Clinical Medicine, Università degli Studi di Firenze, 50134 Florence, Italy.ORCID 0000-0003-2374-5147
Simona SerratìLaboratory of Nanotecnology, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.ORCID 0000-0002-4015-5205
Francesca MargheriDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", Università degli Studi di Firenze, 50134 Florence, Italy.
Anna LaurenzanaDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", Università degli Studi di Firenze, 50134 Florence, Italy.ORCID 0000-0002-8745-3808
Chiara NedianiDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", Università degli Studi di Firenze, 50134 Florence, Italy.ORCID 0000-0003-3190-3539
Silvia PeppicelliDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", Università degli Studi di Firenze, 50134 Florence, Italy.ORCID 0000-0001-6459-0458
Lido CaloriniDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", Università degli Studi di Firenze, 50134 Florence, Italy.ORCID 0000-0002-5508-4200
University of Florence · ITIstituto Tumori Bari · IT

Funding

Istituto Toscano Tumori Decreto Dirigenziale Regione Toscana n.5254 of 04/12/2013
6 · The paper itself

Abstract

The understanding of the molecular mechanisms leading to melanoma dissemination is urgently needed in view of the identification of new targets and the development of innovative strategies to improve patients' outcomes. Within the complexity of tumor intercellular communications leading to metastatic dissemination, extracellular vesicles (EV) released by tumor cells are central players. Indeed, the ability to travel through the circulatory system conveying oncogenic bioactive molecules even at distant sites makes EV capable of modulating recipient cells to facilitate metastatic dissemination. The dynamic remodeling of the tumor microenvironment might influence, along with a number of other events, tumoral EV release. We observed that, in melanoma, extracellular acidosis increases the release of EV enriched in miR-214, an onco-miRNA involved in melanoma metastasis. Then, miR-214-enriched EV were found to induce a state of macrophage activation, leading to an overproduction of proinflammatory cytokines and nitric oxide. Such an inflammatory microenvironment was able to alter the endothelial cell permeability, thereby facilitating the trans-endothelial migration of melanoma cells, a crucial step in the metastatic cascade. The use of synthetic miR-214 inhibitors and miR-214 overexpression allowed us to demonstrate the key role of miR-214 in the EV-dependent induction of macrophage activation. Overall, our in vitro study reveals that the release of tumor miR-214-enriched EV, potentiated by adapting tumor cells to extracellular acidosis, drives a macrophage-dependent trans-endothelial migration of melanoma cells. This finding points to miR-214 as a potential new therapeutic target to prevent melanoma intravasation.

Indexed as

acidic tumor microenvironmentextracellular vesiclesinflammationmelanomamiR-214trans-endothelial migrationvascular permeability

Identifiers

PMID36291876
PMCPMC9599952
OpenAlexW4306737882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.